MajorSemi-synthetic opioid analgesic (μ-agonist)×Fixed-dose combination: weak opioid with SNRI activity plus non-opioid analgesic
Updated · Methodology
Mechanism
Tramadol and oxycodone are both opioid receptor agonists, acting mainly at the mu receptor, so their depressant effects on the central nervous system (CNS) and on breathing add up (tramadol/paracetamol and oxycodone labels, US Food and Drug Administration, FDA). In the documents of both drugs, other opioids appear among the CNS depressants that raise the risk of profound sedation, respiratory depression, coma and death (tramadol/paracetamol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; FDA labels of both drugs). Tramadol has a second mechanism: it weakly inhibits the reuptake of serotonin and noradrenaline. In the oxycodone FDA label, tramadol appears among the serotonergic drugs with which opioids have caused serotonin syndrome. Other opioids also raise the seizure risk of tramadol (tramadol/paracetamol FDA label). CYP3A4 and CYP2D6 break down both drugs, but there is nothing in the labels about one changing the blood levels of the other, or about paracetamol and oxycodone.
Symptoms
Signs of opioid excess are confusion, drowsiness, shallow breathing, pinpoint pupils, nausea and vomiting, and in severe cases life-threatening respiratory and circulatory depression (tramadol/paracetamol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Combined with another central nervous system depressant, the opioid can cause profound sedation, low blood pressure, respiratory depression that can progress to respiratory arrest, coma and death. The risk is highest when treatment starts and after a dose increase (tramadol/paracetamol and oxycodone labels, US Food and Drug Administration, FDA). Serotonin syndrome causes agitation, hallucinations, coma, fast heart rate, labile blood pressure, fever, overactive reflexes, incoordination, muscle rigidity, nausea, vomiting and diarrhoea. It usually starts within hours to a few days of combined use (tramadol/paracetamol FDA label). Seizures have occurred with tramadol at recommended doses, and other opioids raise this risk (tramadol/paracetamol FDA label).
Management
Prescribe two opioids together only when other treatment options are inadequate, at the lowest effective doses and for the shortest time (tramadol/paracetamol and oxycodone labels, US Food and Drug Administration, FDA; tramadol/paracetamol and oxycodone summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If extended-release oxycodone replaces tramadol/paracetamol, stop all other opioids except those taken as needed for breakthrough pain. Start oxycodone at 10 mg every 12 hours, because there are no established conversion ratios from other opioids (oxycodone FDA label). Switch from one opioid to another only after clinical assessment and a careful dose review (oxycodone SmPC, AEMPS). If the patient nevertheless takes both drugs, start oxycodone at one-third to one-half of the recommended starting dose in a patient who already takes a central nervous system depressant. Check breathing, sedation and blood pressure regularly (oxycodone FDA label). In a patient who already takes oxycodone, start tramadol/paracetamol at a lower dose and titrate it to response (tramadol/paracetamol FDA label). Do not exceed 8 tablets of tramadol/paracetamol a day (300 mg tramadol and 2600 mg paracetamol), taken at least 6 hours apart. Above the recommended tramadol doses, the seizure risk rises (tramadol/paracetamol SmPC, AEMPS). Warn the patient and carers about the signs of respiratory depression and sedation (tramadol/paracetamol SmPC, AEMPS) and discuss an opioid overdose reversal agent, naloxone or nalmefene, in advance (FDA labels of both drugs). Naloxone reverses respiratory depression caused by tramadol (tramadol/paracetamol SmPC, AEMPS), but in tramadol overdose it may raise the seizure risk (tramadol/paracetamol FDA label). Tramadol/paracetamol is contraindicated in acute opioid intoxication, including oxycodone overdose (tramadol/paracetamol SmPC, AEMPS). If serotonin syndrome is suspected, stop both drugs (tramadol/paracetamol and oxycodone FDA labels).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Oxicodona, OxyContin 10 mg (nº registro 63446), sección 4.5 (2025)– AEMPS, CIMA, nº registro 63446, revisión 04/2025, secciones 4.4 y 4.5
- FDA: OxyContin (oxycodone hydrochloride) prescribing information (2026)– FDA, DailyMed, setid bfdfe235-d717-4855-a3c8-a13d26dadede, Knoa Pharma, revisión 06/2026, secciones 2.6, 5.3 y 7
- AEMPS: Ficha técnica: Tramadol/Paracetamol, Zaldiar 37,5 mg/325 mg (nº registro 65149), sección 4.5 (2026)– AEMPS, CIMA, nº registro 65149 (Zaldiar 37,5 mg/325 mg comprimidos recubiertos con película, Grünenthal Pharma), revisión 02/2026, secciones 4.2, 4.3, 4.4, 4.5 y 4.9
- AEMPS: Ficha técnica: Oxicodona, Oxicodona Sandoz 10 mg (nº registro 70687), sección 4.5 (2025)– AEMPS, CIMA, nº registro 70687 (Sandoz Farmacéutica), revisión 04/2025, secciones 4.4 y 4.5
- FDA: Tramadol hydrochloride and acetaminophen tablets (Amneal) prescribing information (2026)– FDA, DailyMed setid d51600e2-2f73-483c-9b2e-f142bafff16d (Amneal Pharmaceuticals of New York), versión 34, efectiva 01/2026, Boxed Warning, secciones 5.3, 5.10, 5.11 y 7